Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in cholesterol synthesis, have been suggested to enhance anti-NSCLC effects induced by several anti-tumor agents in which the inhibition of both PI3K/Akt and mitogen-activated protein kinase (MAPK) pathways explain the statins’ sensitization activity [12]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.